Metabolic Control of Immune Suppression in Gliomas

Project: Research project

Project Details

Description

Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain cancer. Even after surgical resection, irradiation and chemotherapy, the median survival for patients with GBM remains at only 14.6 months, with 26% of patients alive after 2 years. The potent immunosuppression induced by GBM is one of the primary obstacles to finding effective immunotherapies. This immunosuppression is associated
with a significant accumulation of regulatory T cells (CD4+CD25+FoxP3+, Tregs) within the tumor
microenvironment and is considered to be one of the primary obstacles inhibiting the tumor rejection functions of CD8+ cytotoxic T cells. It is therefore important that future immunotherapies simultaneously arm effector CD8+ cytotoxic T cells, while at the same time inhibiting immunosuppressive mechanisms. Building on our expertise in brain tumor immunology, we now propose to elucidate the mechanisms involved in GBM immunosuppression and to investigate the function of a novel immunomodulatory agent in the context of a phase I/II human clinical trial. Cumulatively, our studies will comprehensively characterize the immunosuppressive microenvironment of gliomas and test the clinical efficacy of a new drug capable of reversing GBM mediated immune tolerance.
StatusFinished
Effective start/end date5/1/164/30/20

Funding

  • National Institute of Neurological Disorders and Stroke (5R01NS093903-05)

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.